Jefferies (NYSE:JEF) analyst Brian Tanquilut reiterated a Buy rating on Encompass Health (NYSE:EHC) on Monday, setting a price target of $100, which is approximately 23.66% above the present share price of $80.87.
Tanquilut expects Encompass Health to post earnings per share (EPS) of $0.87 for the second quarter of 2021.
The current consensus among 6 TipRanks analysts is for a Strong Buy rating of shares in Encompass Health, with an average price target of $96.4.
The analysts price targets range from a high of $106 to a low of $87.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $1.21 billion and a net profit of $193 million. The company's market cap is $8.03 billion.
According to TipRanks.com, Jefferies analyst Brian Tanquilut is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 7.8% and a 58.82% success rate.
Encompass Health Corp. engages in providing post-acute healthcare services. It operates through the following segments: Inpatient Rehabilitation and Home Health & Hospice. The Inpatient Rehabilitation segment operates inpatient rehabilitation hospitals that provides rehabilitative treatment and care to patients who are recovering from stroke and other neurological disorders, cardiac & pulmonary conditions, brain & spinal cord injuries, complex orthopedic conditions and amputations. The Home Health and Hospice segment provides Medicare-certified home nursing, specialized home care and in-home services. The company was founded by Richard M. Scrushy on February 22, 1984 and is headquartered in Birmingham, AL.